NASDAQ:FENC - Fennec Pharmaceuticals Stock Price, Forecast & News

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Fennec Pharmaceuticals Inc (NASDAQ:FENC) posted its quarterly earnings results on Friday, February, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.05. View Fennec Pharmaceuticals' Earnings History.

Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Fennec Pharmaceuticals.

2 Wall Street analysts have issued 12-month price objectives for Fennec Pharmaceuticals' stock. Their forecasts range from $16.00 to $17.00. On average, they expect Fennec Pharmaceuticals' share price to reach $16.50 in the next year. This suggests a possible upside of 116.0% from the stock's current price. View Analyst Price Targets for Fennec Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fennec Pharmaceuticals.

News stories about FENC stock have been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fennec Pharmaceuticals earned a news impact score of 1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Fennec Pharmaceuticals.

Fennec Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 499,300 shares, an increase of 6.4% from the January 15th total of 469,400 shares. Based on an average daily volume of 37,300 shares, the short-interest ratio is currently 13.4 days. Approximately 3.0% of the shares of the stock are sold short. View Fennec Pharmaceuticals' Current Options Chain.

Some companies that are related to Fennec Pharmaceuticals include Replimune Group (REPL), Agenus (AGEN), Nantkwest (NK), Prevail Therapeutics (PRVL), Compugen (CGEN), Translate Bio (TBIO), Voyager Therapeutics (VYGR), Scholar Rock (SRRK), Autolus Therapeutics (AUTL), Adaptimmune Therapeutics (ADAP), Precision BioSciences (DTIL), Cabaletta Bio (CABA), BioCryst Pharmaceuticals (BCRX), PDL BioPharma (PDLI) and Gritstone Oncology (GRTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Iovance Biotherapeutics (IOVA), Amarin (AMRN), Fate Therapeutics (FATE), Allena Pharmaceuticals (ALNA), Coherus Biosciences (CHRS), Denali Therapeutics (DNLI), Karyopharm Therapeutics (KPTI), Pieris Pharmaceuticals (PIRS), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

Fennec Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Kam Lawrence (4.20%), Oxford Asset Management LLP (0.30%), Hartford Financial Management Inc. (0.18%), Wedbush Securities Inc. (0.12%), Renaissance Technologies LLC (0.12%) and Goldman Sachs Group Inc. (0.07%). View Institutional Ownership Trends for Fennec Pharmaceuticals.

FENC stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP and Victory Capital Management Inc.. View Insider Buying and Selling for Fennec Pharmaceuticals.

FENC stock was purchased by a variety of institutional investors in the last quarter, including Kam Lawrence, Renaissance Technologies LLC, Goldman Sachs Group Inc., Wedbush Securities Inc. and Hartford Financial Management Inc.. View Insider Buying and Selling for Fennec Pharmaceuticals.

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FENC stock can currently be purchased for approximately $7.64.

Fennec Pharmaceuticals has a market capitalization of $152.01 million. The company earns $-12,770,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. View Additional Information About Fennec Pharmaceuticals.

The official website for Fennec Pharmaceuticals is http://www.fennecpharma.com/.

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.